Tepezza Lawsuit: Is a Settlement Finally Coming in 2026?

If you’re searching for a direct answer on the Tepezza lawsuit, here it is: no settlement has been officially announced as of mid-2026, but the signs are pointing in that direction. A federal judge recently struck all upcoming bellwether trial deadlines without dismissing a single claim, and that kind of move usually means serious settlement talks are happening behind closed doors. If you or a family member developed permanent hearing loss or tinnitus after Tepezza treatment, this is the moment to understand exactly where things stand.

This article breaks down the Tepezza lawsuit in plain language: what it alleges, where the case stands in court right now, and my honest opinion on what the recent trial delays actually mean. None of this is legal advice. It’s an informed take based on public court records, meant to help you make sense of a litigation process that moves slowly and rarely explains itself clearly to the people it affects most.

Tepezza Lawsuit at a Glance

Detail	Status as of Mid-2026
Litigation type	Multidistrict litigation (MDL 3072)
Court	U.S. District Court, Northern District of Illinois
Presiding judge	Judge Thomas Durkin
Pending cases	~273 (as of January 2026)
Drug manufacturer	Horizon Therapeutics (now part of Amgen)
FDA approval date	2020
Updated warning label	July 2023
Settlement announced?	No official settlement as of mid-2026
First bellwether trial	No earlier than August 2026 (deadlines currently paused)

What Is the Tepezza Lawsuit About?

The Tepezza lawsuit centers on a drug called teprotumumab, sold under the brand name Tepezza, which the FDA approved in 2020 to treat thyroid eye disease. Soon after the drug hit the market, patients began reporting hearing loss and tinnitus, side effects that weren’t on the original label. The FDA required an updated warning label in July 2023, instructing doctors to monitor patients’ hearing during treatment.

Plaintiffs in the Tepezza lawsuit allege that Horizon Therapeutics knew or should have known about the hearing risks well before that label update and failed to warn patients and doctors in time. Independent research backs up the concern:

Study	Patients Studied	Key Finding
Endocrine Society (2021)	26 patients, 4+ infusions	65% developed hearing problems vs. ~10% reported in clinical trials
American Journal of Ophthalmology (2022)	27 patients	81.5% developed new or worsening hearing symptoms; only 45.5% saw resolution

The case was originally headed toward a series of bellwether trials, individual test cases used to gauge how juries respond to the evidence before a broader settlement is negotiated. The first bellwether trial in this Tepezza lawsuit was pushed back multiple times throughout 2025, eventually landing on a June 2026 start date. Then, in October 2025, the presiding magistrate judge struck all remaining bellwether deadlines following an off-the-record conference with both sides’ attorneys.

Bellwether Trial Schedule: Then vs. Now

Stage	Originally Proposed	Most Recent Status
Trial 1	March–April 2026	Paused (no earlier than August 2026)
Trial 2	June 2026	Pending settlement talks
Trial 3	August–September 2026	Pending settlement talks
Trial 4	September–November 2026	Pending settlement talks

My Take: What the Paused Trial Dates Really Mean

Here’s where I’ll offer an actual opinion rather than just reporting facts. Courts don’t typically cancel trial dates without explanation unless something is shifting behind the scenes. In the Tepezza lawsuit, the judge didn’t dismiss any claims and didn’t issue a ruling against either side. Lawyers in the case had also been required to hold settlement discussions every three months for nearly a year leading up to this decision. Put those two things together, and it strongly suggests the parties are negotiating toward a global resolution rather than preparing for trial.

That said, “likely settling” and “has settled” are very different things, and I think some legal marketing sites blur that line more than they should. If a webpage tells you there’s already a confirmed 2026 settlement pool with specific payout tiers, treat that claim with real skepticism. As of mid-2026, no official Tepezza settlement has been announced, and no court-approved claim form exists.

Who Qualifies for a Tepezza Lawsuit Claim?

Likely to Qualify	Less Likely to Qualify
Received Tepezza infusions for thyroid eye disease	Never received Tepezza infusions
Treated between January 2020 and July 2023	Treated after July 2023, once the warning label existed
Hearing loss, tinnitus, or ear fullness began during or shortly after treatment	Hearing symptoms began years after treatment ended, with no clear link
Have audiology records documenting the onset of symptoms	No medical documentation tying symptoms to treatment timing

The timing matters because claims are stronger when the hearing damage began during or shortly after treatment and when treatment predates the 2023 label change that added the hearing-risk warning. If your hearing symptoms started years after treatment ended, proving the drug caused the damage becomes more difficult, though not necessarily impossible. This is exactly the kind of detail a products liability attorney can evaluate properly, since causation in drug injury cases depends heavily on medical timing and records.

What Happens If the Bellwether Trials Actually Go Forward

If settlement talks break down, the Tepezza lawsuit bellwether trials will proceed with a small group of representative cases, currently expected to begin no earlier than August 2026. These trial outcomes wouldn’t be legally binding on every other case in the MDL, but they tend to set the tone for how much manufacturers are willing to offer in a broader settlement. A large plaintiff verdict in an early trial generally pushes settlement values up; a defense win can do the opposite.

In my opinion, this is the real reason the next few months matter so much for anyone watching the Tepezza lawsuit. Whether the case resolves through negotiation or trial, the next status conference and any further docket activity will tell us a lot more than speculation can.

What You Should Do If You Believe You Have a Claim

If you took Tepezza and developed lasting hearing problems, the most useful step right now isn’t waiting for a settlement announcement. It’s gathering your records. A Tepezza lawsuit claim, like most drug injury cases, depends heavily on documentation, and it’s much easier to gather now than years from now.

Quick checklist before contacting an attorney:

• Dates of all Tepezza infusions
• Audiology or ENT records showing when hearing symptoms began
• Diagnosis records for thyroid eye disease and/or Graves’ disease
• Any communication from your doctor about Tepezza’s risks at the time of treatment
• A personal timeline connecting treatment dates to when symptoms started

Beyond that, consult a products liability attorney who specifically handles MDL litigation. Many offer free initial consultations, and there’s typically no upfront cost since these cases are usually handled on contingency. Be cautious of any site that pressures you to “act now or lose eligibility,” since legitimate deadlines in MDL litigation are set by courts, not by marketing copy.

Informative Resources

• FDA Drug Safety Communications — official record of the July 2023 labeling change adding hearing loss warnings.
• U.S. Courts – Multidistrict Litigation Overview — explains how MDL consolidation works for cases like the Tepezza lawsuit.
• Judicial Panel on Multidistrict Litigation — official docket reports tracking the size and status of MDL 3072.
• PACER – Federal Court Records — search the Northern District of Illinois docket directly for the latest filings.
• National Institute on Deafness and Other Communication Disorders — general information on hearing loss and tinnitus causes and treatment.

Key Takeaways

• As of mid-2026, no official settlement has been announced in the Tepezza lawsuit, and no court-approved claim form exists.
• Roughly 273 cases are pending in the federal MDL in the Northern District of Illinois as of January 2026.
• A judge struck all bellwether trial deadlines in October 2025 without dismissing claims, a sign that settlement talks may be advancing.
• Bellwether trials, if they proceed, are now expected no earlier than August 2026.
• Most viable claims involve Tepezza treatment between 2020 and July 2023, before the FDA’s hearing-loss warning was added to the label.
• Independent studies found hearing damage rates between 65% and 81.5% among patients studied, far above original clinical trial disclosures.
• Be skeptical of websites advertising guaranteed payout tiers before any official settlement is confirmed.
• Gathering medical and audiology records now is more useful than waiting for a settlement announcement.

FAQs

Disclaimer:

This article is for informational purposes only and does not constitute legal or medical advice. Litigation status changes frequently; confirm the current status through official court records or a licensed attorney before making any decisions about a claim.